Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML
Sign Up to like & getrecommendations! Published in 2022 at "Blood Advances"
DOI: 10.1182/bloodadvances.2022007334
Abstract: Key points In the phase 3 PANTHER trial, EFS was similar between arms in the intent-to-treat population and in patients with higher-risk MDS. A signal for improved overall survival for pevonedistat+azacitidine was seen in higher-risk… read more here.
Keywords: risk mds; pevonedistat plus; higher risk; plus azacitidine ... See more keywords